Do you want to read an article? Please log in or register.
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Migraine and Headache
Related content
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
Migraine and Headache
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies
Headache.
Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C
doi: 10.1111/head.13636.
RECOMMENDED
Migraine and Headache
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T
doi: 10.1177/0333102420905321.
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
RECOMMENDED
Migraine and Headache
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Lancet.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB
doi: 10.1016/S0140-
Migraine and Headache
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Lancet Neurol.
Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC
doi: 10.1016/S1474-4422(20)30279-9.
Psychosis and Schizophrenia
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Lancet Psychiatry.
Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S
doi: 10.1016/
RECOMMENDED
Migraine and Headache
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Neurology.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK
doi: 10.1212/WNL.
RECOMMENDED
Migraine and Headache
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
doi: 10.1177/0333102420905132.